Compare Norfolk Southern Corporation (NSC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Norfolk Southern Corporation trades at $317.62 (market cap $71.20B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Norfolk Southern Corporation is far larger — about 7× State Street SPDR S&P Biotech ETF's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NSC | XBI | |
|---|---|---|
Market Cap | $71.20B | $10.11B |
Volume | 555,248 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $352.98 | $169.55 |
52-Week Low | $278.19 | $104.99 |
Typical Hold Time | 33 Days | 38 Days |
Enterprise Value | $86.75B | — |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $317.67, up 1.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with a strong net income margin of 21.02% (2026). Positive sentiment surrounds the proposed merger with Union Pacific, which is advancing through regulatory review and is backed by over 500 customers, as reported by Business Wire on September 22, 2026.
The outlook is positive, with a consensus price target of $361.86 offering ~14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures on margins and regulatory hurdles for the combination. Earnings on October 22, 2026, will be a critical catalyst.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
